TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Inclusion Criteria: Pediatric patients with hematological malignancies in complete remission (CR), partial remission (PR) or with stable disease * Acute myeloid leukemia (AML): Patients with high-risk AML in CR1 Patients with relapsed or primary therapy-refractory AML * Acute lymphoid leukemia (ALL): Patients with high-risk ALL in CR1 Patients with relapsed or primary refractory ALL Exclusion Criteria: * Age \>18 years or \<8 weeks * Patients with progressive disease prior HCT * \<3 months after preceding hematopoietic cell transplantation (HCT) * History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukencephalopathy, active CNS infection) * Fungal infections with radiological and clinical progression * Liver function abnormalities with bilirubin \>2 mg/dL and elevation of transaminases higher than 400 U/L * Chronic active viral hepatitis * Ejection fraction \<40% or shortening fraction \<25% on echocardiography * Patients with \> grade II hypertension by Common Toxicity Criteria (CTC) * Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard * Respiratory failure necessitating supplemental oxygen * HIV infection * Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study * Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction) * Patients unwilling or unable to comply with the protocol or unable to give informed consent * Treatment with any investigational product within 4 weeks prior to study treatment (transfusion of the IMP)